O I GLASS INC (OI)
Sector: Materials
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Materials
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for OI
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| OI | Former Chief Financial Officer and Executive Director at GlaxoSmithKline plc | 64 | ["Global Manufacturing, Supply Chain, & Safety", "Senior Public Company Leadership", "Market & Commercial Experience", "Corporate Governance", "Financial Oversight & Capital Allocation", "Strategy & Corporate Development", "Enterprise Risk Management", "Engineering & Product Development", "Cybersecurity, Data Privacy, & AI", "Sustainability & Climate Oversight", "extensive global business experience", "financial reporting expertise", "public company leadership experience", "Chief Financial Officer at GSK", "Group Finance Director at HSBC", "chartered accountant", "senior finance leadership roles at HSBC, GE, Schlumberger"] | ["Audit", "People and Remuneration Committee", "Nomination Committee", "Transactions Committee", "Audit and Risk Committee"] | 2026 |
Biography sourced from the proxy statement filing.
Age: 64 Director Since: 2025 Committees: Audit Mr. Mackay s extensive global business experience, financial reporting expertise, and public company leadership experience qualify him to serve on the Company s Board. Mr. Mackay was the Chief Financial Officer and Executive Director at GlaxoSmithKline plc (GSK), a British multinational pharmaceutical and biotechnology company, from 2019 to 2023. During his time at GSK, Mr. Mackay played a leading role in restructuring the company, including the demerger of its consumer healthcare division in 2022 to form Haleon plc, a new public company with annual revenues exceeding 10 billion, listed on the London Stock Exchange. Prior to joining GSK in early 2019, Mr. Mackay was Group Finance Director of HSBC Holdings plc, a position he held for eight years, serving on the board as executive director from December 2010 until the end of 2018 . In his earlier career he undertook senior finance leadership roles for: HSBC in North America and Asia; for the General Electric Company of the US for almost 12 years in diverse areas including Consumer Finance, Healthcare and Corporate Audit; and for Schlumberger in Africa and Asia. A chartered accountant, Mr. Mackay s formative career was with Thomson McLintock in Aberdeen and with Price Waterhouse in New York and Paris. In July 2022, Mr. Mackay became a non-executive director at National Grid plc where he is chair of the Audit and Risk Committee and member of the People and Remuneration Committee and Nomination Committee. He previously served on the board of directors of GSK plc from 2019 to 2023. In November 2023 and January 2024, respectively, he joined UK Government Investments Limited (UKGI) and Schroders plc as a non-executive director. He chairs the Transactions Committee at UKGI and the Audit and Risk Committee at Schroders. In July 2024, he stepped down from his role as an Independent Member of the Court of the University of Aberdeen and Chair of its Remuneration Committee. Mr. Mackay holds an MA in Business Studies and Accounting and an Honorary Doctorate from Aberdeen University in Scotland.